Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.8%

4 terminated/withdrawn out of 221 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

13%

28 trials in Phase 3/4

Results Transparency

0%

0 of 68 completed trials have results

Key Signals

39 recruiting

Enrollment Performance

Analytics

N/A
72(44.2%)
Phase 2
36(22.1%)
Phase 1
21(12.9%)
Phase 4
17(10.4%)
Phase 3
11(6.7%)
Early Phase 1
6(3.7%)
163Total
N/A(72)
Phase 2(36)
Phase 1(21)
Phase 4(17)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (221)

Showing 20 of 221 trials
NCT07040072Phase 1Recruiting

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Role: lead

NCT07291960Not Yet Recruiting

Retinal Clinical Assessment With AI-derived Quantitative Information

Role: lead

NCT07554482Phase 2Not Yet Recruiting

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Role: lead

NCT06140992Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Role: collaborator

NCT07461831Phase 2Active Not Recruiting

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Role: lead

NCT07523737Phase 2Recruiting

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Role: lead

NCT07525466Phase 1Recruiting

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Role: lead

NCT07524959Not ApplicableNot Yet Recruiting

Antagonism of Neostigmine in Continuous Infusion of Mivacurium

Role: lead

NCT06429527Not ApplicableEnrolling By Invitation

Evaluating App-Based Vision Testing (WHOeyes) Combined With the Questionnaire as a Substitute for One-Week Postoperative In-Clinic Follow-Up in Age-Related Cataract Patients: A Multi-center Randomized Controlled Trial

Role: collaborator

NCT07499791Phase 2Not Yet Recruiting

Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis

Role: lead

NCT07472764Not ApplicableNot Yet Recruiting

Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children

Role: lead

NCT07441993Phase 2Recruiting

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Role: collaborator

NCT07412678Not ApplicableNot Yet Recruiting

Evaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia

Role: lead

NCT07406399Phase 4Completed

Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia

Role: lead

NCT07208617Not ApplicableNot Yet Recruiting

Development of Bioluminescent Myopia Prevention and Control Instrument and Evaluation of Its Effect on Myopia

Role: lead

NCT07371923Phase 2Recruiting

Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

Role: lead

NCT07355699Phase 4Recruiting

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Role: lead

NCT06647732Phase 2Recruiting

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Role: collaborator

NCT07323251Not ApplicableRecruiting

Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression

Role: lead

NCT07032909Not ApplicableCompleted

Evaluating the Effectiveness of Comfort Reading Mode in Preventing Dry Eyes and Visual Fatigue

Role: lead